Public Service Enterprise Group (PEG) stock has reached a 52-week low of $72.52, marking an 11.11% decline over the past year and trading about 17% below its 52-week high. Despite this downturn and mixed Q2 2026 financial results where revenue fell short of projections, the company maintains a strong dividend profile with 56 consecutive years of payments and a current yield of 3.64%. Management has reaffirmed full-year earnings guidance, emphasizing ongoing utility investment, robust nuclear operations, and improving regulatory support for future growth.

NorthWestern Energy plans an overnight power outage in central Great Falls on Friday for a system upgrade, impacting customers north of 10th Avenue South to 3rd Avenue South and west of 16th Street South to 3rd Street South. The outage will begin at midnight and is expected to be restored by 5 a.m., with affected customers receiving phone notifications. This work is necessary to replace aging substation equipment and ensure reliable electric service.

Simon Property (SPG) shares have fallen 3.5% since its last earnings report, underperforming the S&P 500. Despite this, the company reported strong Q2 2026 results, with FFO and total revenues beating estimates, driven by broad-based leasing demand and higher traffic. Simon Property also raised its full-year 2026 Real Estate FFO outlook, indicating potential for future recovery.

Sempra Energy's stock has reached a 52-week low of $19.88, trading 17% below its 52-week high of $23.84. The energy company has seen its stock decrease by 9.92% over the past year, reflecting broader market trends and company-specific challenges. Investors are now reevaluating their positions in light of this downturn.

Duke Energy's preferred stock (DUK -1.16%, DUKB -0.77%) has dropped to a 52-week low of $21.75, representing an 8% decline from its high of $25.30 over the past year. This downturn is attributed to fluctuating market conditions and investor concerns within the energy sector, despite the stock's low beta of 0.36. InvestingPro rates the company's financial health as "Fair."

The West Virginia Public Service Commission has denied requests to delay evidentiary proceedings for NextEra Energy Transmission's 107.5-mile MidAtlantic Resiliency Link (MARL) transmission project. Despite concerns raised by PSC staff and NextEra's agreement to a delay, the commission ruled against it, stating the circumstances did not justify an extension. The project, intended to address emerging grid needs and projected demand increases, will proceed with hearings scheduled from October 26 to November 2.

Verizon Communications Inc. has declared a quarterly dividend of 70.75 cents per outstanding share, payable on November 2, 2026, to shareholders of record by October 9, 2026. CEO Dan Schulman emphasized the company's consistent return of capital to shareholders, driven by strong operational execution and sustainable cash flow. Verizon generated $138.2 billion in revenues in 2025 and made approximately $11.5 billion in cash dividend payments the same year.

Optical Cable Corp. (OCC) reported strong fiscal Q3 2026 results with significant increases in sales, gross profit, and net income, driven by robust demand in enterprise, data center, and specialty markets. Despite these positive financial outcomes and an increased backlog, the company's stock fell in premarket trading. Management attributed the success to higher volumes and improved operating leverage, while acknowledging ongoing challenges such as optical fiber shortages and longer raw material lead times.

Autodesk has launched a new emotionally-driven campaign titled "The World Is Yours for the Making" in collaboration with Giant Spoon. The campaign, directed by Salomon Ligthelm and using Autodesk's Design and Make tools, questions what is still worth making in a world where technology can create almost anything. It focuses on the human element, choices, and care behind significant things in our lives rather than the software itself.

AbbVie executives presented their growth strategy at a Wells Fargo conference, focusing on the continued success of their SKYRIZI and RINVOQ immunology franchises and an expanding pipeline in oncology and neuroscience. The company expects significant growth drivers from new indications for its key immunology drugs, anticipates a rapid regulatory filing for its cancer therapy etentamig, and maintains its outlook for high-single-digit annual revenue growth through the decade. AbbVie also detailed its strategic approach to business development and increased R&D spending to fuel innovation.